Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04790903 · Hoffmann-La Roche · PHASE1 · terminated · last registry update 2024-07-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the BO42203 study.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-05Phase 3 first posted: Kura Oncology, Inc., Ziftomenib + Placebo (NCT07007312)
- 2025-04-24Phase 3 first posted: BeOne Medicines, Sonrotoclax + Obinutuzumab (NCT06943872)
- 2025-03-13Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Pembrolizumab (NCT04284787)
- 2025-02-28Phase 3 first posted: Janssen Research & Development, LLC, Bleximenib + Venetoclax (VEN) (NCT06852222)
- 2025-02-26Phase 3 first posted: BeOne Medicines, Tacabrutideg + Bendamustine (NCT06846671)
- 2025-01-27Results posted on the registry: National Cancer Institute (NCI), Navitoclax + Trametinib (NCT02079740)
- 2025-01-14Results posted on the registry: AbbVie, Ibrutinib + Venetoclax (NCT04477486)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-22Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Revumenib + Placebo (NCT06652438)
- 2024-10-15Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Azacitidine Injection (NCT06641414)
- 2024-05-24Phase 3 first posted: AbbVie, Venetoclax + Acalabrutinib (NCT06428019)
- 2024-04-23Results posted on the registry: Dana-Farber Cancer Institute, IBRUTINIB + Venetoclax (NCT04273139)
- 2024-03-20Phase 3 first posted: Ascentage Pharma Group Inc., Lisaftoclax (APG-2575) + Acalabrutinib (NCT06319456)
- 2023-10-27Phase 3 first posted: Ascentage Pharma Group Inc., lisaftoclax +BTK inhibitor + BTK inhibitor (NCT06104566)
- 2023-10-10Phase 3 first posted: BeOne Medicines, Sonrotoclax + Zanubrutinib (NCT06073821)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BCL2 (NCT06073730)
- 2023-09-18Results posted on the registry: Takeda, Pevonedistat + Venetoclax (NCT04266795)
- 2023-07-17Phase 3 first posted: Merck Sharp & Dohme LLC, Nemtabrutinib + Venetoclax (NCT05947851)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision